



**Xtandi (Enzalutamide)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
 AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page





**Xtandi (Enzalutamide)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES: <input type="checkbox"/> Metastatic castration-resistant prostate cancer <input type="checkbox"/> Non-Metastatic castration-resistant prostate cancer <input type="checkbox"/> Metastatic castration-sensitive prostate cancer <input type="checkbox"/> Other Diagnosis _____ ICD-10 Code(s): _____		ICD-10:
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
For Non-Metastatic castration-resistant prostate cancer: Does the prostate cancer have neuroendocrine differentiation, signet cell features, or small-cell features? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient been receiving androgen-deprivation therapy (such as flutamide, enzalutamide, bicalutamide, nilutamide) or a gonadotropin releasing hormone (such as Lupron Depot, Zolodex, Elidex, or Trelstar LA) ? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation of therapy(s) and dates of service.</i> Has the patient undergone bilateral orchiectomy? <input type="checkbox"/> Yes <input type="checkbox"/> No Will patient continue on androgen-deprivation therapy while taking Xtandi? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have castration-associated testosterone levels equaling no greater than 1.73nmol/L (0.50ng/L)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit lab documentation.</i> Does the patient have at least ONE prostate-specific antigen(PSA) value equaling 2ng/ml or greater? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient had at least THREE rising prostate-specific antigen (PSA) values in the past 10 months, obtained at an interval of at least one week apart during androgen deprivation? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit lab documentation.</i> Is the patient's PSA doubling time of 10 months or less? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit copies of all PSA levels obtained in the past 10months, required for review.</i> Has the patient received prior treatment with any of the following: aminoglutethimide, ketoconazole, abiraterone acetate, or enzalutamide? <input type="checkbox"/> Yes <input type="checkbox"/> No		





**Xtandi (Enzalutamide)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Has the patient received prior treatment with any investigational agent that inhibits androgen receptors or androgen synthesis? Yes No

For metastatic castration-sensitive prostate cancer:

Are the patient's metastases noted on computed tomography(CT) and/or bone scan? Yes No
Please submit the imaging report.

Was testosterone suppression initiated within the past 3 months? Yes No
Please submit chart documentation.

Did patient undergo no more than 24 months of adjuvant testosterone suppression AND discontinued it 12 or more months ago? Yes No *Please submit chart documentation.*

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program; c/o Magellan Health, Inc.
4801 E. Washington Street, Phoenix, AZ 85034
Phone: 877-228-7909

